Archimej Technology raised 1.9 million Euros to boost the development of its flagship project line : Beta-Bioled Evry, France – December 7th, 2015. Archimej Technology, a French innovative company focused on the development of portable blood analyzers for personal medical diagnostic, announced today the closing, on October 31, 2015, of a 1.9 Million Euros equity investment by two major Chinese and Hongkongese investors plus a Chinese opinion-leader in In-Vitro Diagnostic (IVD). The world (...)
The companies OsseoMatrix and Ynsect and the laboratory Généthon were among the 16 laureates of the second phase of the Worldwide Innovation 2030 Challenge, an initiative of the French State launched in 2013 to foster the emergence of innovative projects in sectors strategic for France. Representatives of the three Genopole entities were received April 28th by President of France François Hollande and Innovation 2030 Commission Chair Anne (...)
The company is undertaking development of its first drug candidate and its companion diagnostic in oncology. PEP-Therapy, a biotechnology company developing targeted therapies for cancer treatments, has raised €1.3 million in initial fund ing. This sum, invested by the Quadrivium 1 seed fund and a business angel, Dr Bernard Majoie, will enable PEP-Therapy to undertake regulatory development of its first therapeutic product, associated with a predictive biomarker for foreseeing the (...)
Tuesday April 28, during a ceremony at the Elysee Palace, Généthon, the laboratory of the AFM-Telethon, was named recipient of the Global Innovation Competition 2030 in the category "Risk lift." A prize that rewards the expert laboratory and world leader in the field of gene therapy for the development of an industrial production process of gene therapy vectors.
Cristal Union and Global Bioenergies are announcing today that they have formed IBN One, a joint venture to build and operate the first plant in France converting renewable resources into isobutene. IBN- One is a société anonyme (limited liability corporation) with share capital of €1,000,000, jointly owned by Cristal Union and Global Bioenergies.
A clinical trial of gene therapy has been conducted by Genethon* in France and in Great Britain and treated 7 children suffering from the Wiskott Aldrich Syndrome. Preliminary results published this week in JAMA are extremely encouraging. The genetic disease of the immune system called « Wiskott Aldrich Syndrome » is induced by the mutation of the WAS gene which, when functional, produces the WAS protein essential to the function of white blood cells and the production of blood platelets. (...)